ClinicalTrials.gg
RecruitingNCT06529978INvENIUpdated Jul 14, 2026

Endocardial Mapping With the CoreMap EP Mapping System

An interventional study of CoreMap EP Mapping System Mapping and CoreMap EP Mapping System Map-Guided Ablation in Persistent Atrial Fibrillation, sponsored by CoreMap Inc.. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by CoreMap Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
245
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
235th of 679
245 · median 127
Started
2024
with 53 others
No phase
405 of 993
67 open now
Primary completion
2026-12
later than 67 of 219 live
Registered
892nd of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 235th largest by planned enrollment of the 679 interventional ones that give a count, is one of 54 that started in 2024, is one of 405 with no phase, reaches primary completion later than 67 of the 219 other live ones, and was the 892nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This is a global, multi-site, prospective, feasibility study.

Read the detailed description

The INvENI Study consists of three phases:

Phase 1, the goal is to collect and analyze high fidelity endocardial electrograms (EGMs) in patients with persistent AF (PerAF) and long-standing persistent AF and to demonstrate safety.

Phase 2, the goal is the initial development and evaluation of a CoreMap-guided tailored ablation strategy and to demonstrate safety and effectiveness of the CoreMap EP Mapping System in patients with PerAF and long-standing persistent AF.

Phase 3, the goal is to evaluate the safety and effectiveness of the CoreMap EP Mapping System's ability to identify spatially constrained AF drivers and guide ablation therapy in PerAF patients with no history of prior AF ablation. This phase aims to demonstrate safety and effectiveness compared to a control arm.

03

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has persistent or long-standing persistent AF, at the discretion of the investigator (Phase 1 \& 2)
  2. Subject has PerAF with no history of prior AF ablation therapy (Phase 3)
  3. Subject is 18 to 80 years of age
  4. Subject has presence of AF-related symptoms and is scheduled for clinically indicated standard of care AF ablation to manage PerAF (Phase 2 or 3) or long-standing PerAF (Phase 2)
  5. Subject is able to provide written
  6. Subject is able and willing to complete all study procedures

Exclusion criteria

Exclusion Criteria:

  1. Any of the following within three months of enrollment:

    1. Myocardial infarction (MI)
    2. Any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation
    3. Confirmed thrombus on imaging
  2. Any of the following within six months of enrollment:

    1. Cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy
    2. Thromboembolic event (stroke)
  3. Any of the following cardiac conditions:

    1. (NYHA) IV
    2. (LVEF) \< 30%
    3. Left atrial diameter >55mm (anterioposterior) (Phase 3)
    4. Carotid stenting or endarterectomy
    5. Atrial or ventricular septal closure or left atrial appendage closure
    6. Implanted permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator; loop recorders are permitted.
    7. Presence of intramural thrombus, tumor (including atrial myxoma), or other abnormality that precludes vascular access, catheter introduction, or manipulation
    8. Unstable angina
    9. Prior mitral or tricuspid valve surgery, repair, prosthetic or mechanical valve
    10. Moderate to severe mitral valve stenosis or other severe valvular disease
    11. Any blood clotting or bleeding abnormalities
  4. to systemic anticoagulation
  5. AF secondary to electrolyte imbalance, acute alcohol intoxication, or reversible or non-cardiac cause
  6. (BMI) > 40 kg/m2
  7. Severe pulmonary disease, pulmonary hypertension, or any chronic respiratory condition
  8. Renal failure requiring dialysis or transplant
  9. Acute illness, active systemic infection, or sepsis
  10. Active drug or alcohol dependency
  11. Hypertrophic cardiomyopathy or cardiac amyloidosis
  12. Cor pulmonale
  13. Any contra-indication that may extend procedure time, at the discretion of the operator
  14. Any woman known to be pregnant or breastfeeding, or any woman of who is not on a reliable form of birth regulation method or abstinence
  15. Subject considered part of vulnerable population
  16. less than one year
  17. Employee of the study site or Sponsor
  18. Subjects who are currently enrolled in another study that would directly interfere with this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
245 participants (estimated)

Study arms

  • Experimental
    Phase 1- Mapping Only

    For Phase 1, the goal is to collect and analyze high fidelity endocardial electrograms (EGMs) in patients with persistent AF (PerAF) and long-standing persistent AF and to demonstrate safety.

    Device: CoreMap EP Mapping System Mapping

  • Experimental
    Phase 2- Map Guided Ablation

    The Phase 2 goal is the initial development and evaluation of a CoreMap-guided tailored ablation strategy and to demonstrate safety and effectiveness of the CoreMap EP Mapping System in patients with PerAF and long-standing persistent AF..

    Device: CoreMap EP Mapping System Mapping · Device: CoreMap EP Mapping System Map-Guided Ablation

  • Experimental
    Phase 3 - Map Guided Ablation

    For Phase 3, the goal is to evaluate the safety and effectiveness of the CoreMap EP Mapping System's ability to identify spatially constrained AF drivers and guide ablation therapy in PerAF patients with no history of prior AF ablation therapy. This phase aims to demonstrate safety and effectiveness compared to a control arm.

    Device: CoreMap EP Mapping System Mapping · Device: CoreMap EP Mapping System Map-Guided Ablation

Interventions

  • DeviceCoreMap EP Mapping System Mapping

    Endocardial mapping to collect and analyze high fidelity endocardial EGMs in patients with persistent and long-standing persistent AF.

  • DeviceCoreMap EP Mapping System Map-Guided Ablation

    Initial development and evaluation of a map-guided tailored ablation strategy and to demonstrate safety and chronic efficacy of the CoreMap EP Mapping System.

06

What researchers measure

Primary outcomes

  1. Phases 1 and Phase 2 Primary Endpoint:

    Incidence of study device related serious adverse events within seven (7) days of the study procedure.

    Time frame: 7 days

  2. Phase 2 and Phase 3 Primary Effectiveness Endpoint:

    Freedom from documented recurrence of AF, atrial tachycardia (AT), or atrial flutter (AFL) based on electrocardiographic data through a 12-month follow-up and excluding a 90-day blanking period.

    Time frame: 6 and 12 months

Secondary outcomes

  1. Phase 1 Secondary Endpoint:

    Successful completion of the intended study mapping procedure with the CoreMap EP Mapping System.

    Time frame: perioperatively/periprocedurally

  2. Phase 2 Secondary Endpoints:

    AF rhythm change or termination following CoreMap-guided ablation.

    Time frame: perioperatively/periprocedurally

  3. Phase 3 Secondary Endpoints:

    AF rhythm change or termination following CoreMap-guided ablation vs. PVI+PW ablation of control arm.

    Time frame: perioperatively/periprocedurally

07

Study locations

4 of 4 sites recruiting
  • NCH Downtown Baker Hospital
    Naples, Florida 34102, United States
    Enrolling by invitation
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
    Enrolling by invitation
  • Virginia Commonwealth University (VCU)
    Richmond, Virginia 23284, United States
    Enrolling by invitation
  • Na Homolce Hospital
    Praha Klanovice, Czechia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 29 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 31, 2024
StartActual
Jul 25, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06529978
Lead sponsor
CoreMap Inc.
Responsible party
Sponsor
First posted
Jul 31, 2024
Start date
Jul 25, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 14, 2026

Study contacts

Jim Foster, SysEng
Contact
jfoster@coremapmedical.com
6178723908
Sarah Kalil
Contact
skalil@coremapmedical.com
Sarah Kalil
study director · CoreMap Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion